• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

145.21 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 35
Open 145.21
Bid (Size) 144.02 (100)
Ask (Size) 146.37 (100)
Prev. Close 145.21
Today's Range 145.21 - 145.21
52wk Range 93.37 - 157.29
Shares Outstanding 1,253,809,440
Dividend Yield 2.18%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗
March 16, 2026
Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology. 
Via The Motley Fool
Topics Regulatory Compliance
Movers and shakers in today's after-hours session for S&P500 stocks? ↗
March 16, 2026
Via Chartmill

Performance

YTD
+19.4%
+19.4%
1 Month
-6.5%
-6.5%
3 Month
+21.2%
+21.2%
6 Month
+29.0%
+29.0%
1 Year
+29.4%
+29.4%

More News

Read More
News headline image
2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch
March 16, 2026
Via Barchart.com
News headline image
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years ↗
March 11, 2026
Via Benzinga
GILEAD SCIENCES INC (NASDAQ:GILD): A Durable Dividend Stock for Income Investors ↗
March 10, 2026
Via Chartmill
News headline image
2 Recession-Resistant Dividend Stocks to Buy Now ↗
March 11, 2026
Via The Motley Fool
Topics Economy
News headline image
What 16 Analyst Ratings Have To Say About Gilead Sciences ↗
March 10, 2026
Via Benzinga
News headline image
3 Blue-Chip Stocks Built for a Rotating Market ↗
March 08, 2026
Via MarketBeat
News headline image
These 3 Cash Flow Machines Provide Stability in Uncertain Markets ↗
March 06, 2026
Via MarketBeat
News headline image
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing ↗
March 04, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Compugen (CGEN) Q4 2025 Earnings Call Transcript ↗
March 02, 2026
Via The Motley Fool
Topics Earnings
News headline image
Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia
March 02, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Arcellx President Sells $10 Million Worth of Shares After Acquisition Announcement ↗
March 02, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Arcellx President Sells $10M Worth of Shares After Acquisition Announcement ↗
March 02, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
P/E Ratio Insights for Gilead Sciences ↗
February 27, 2026
Via Benzinga
What's going on in today's session: S&P500 movers ↗
February 27, 2026
Via Chartmill
Uncover the latest developments among S&P500 stocks in today's session. ↗
February 27, 2026
Via Chartmill
News headline image
Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector?
February 27, 2026
Via Barchart.com
Topics ETFs
News headline image
Kymera (KYMR) Q4 2025 Earnings Call Transcript ↗
February 26, 2026
Via The Motley Fool
Topics Earnings
News headline image
Merck's Two-Drug HIV Regimen Challenges Industry Standards Following Positive Phase 3 Results
February 26, 2026
Via MarketMinute
Topics Intellectual Property
News headline image
Arcus (RCUS) Q4 2025 Earnings Call Transcript ↗
February 25, 2026
Via The Motley Fool
Topics Earnings
News headline image
Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance
February 25, 2026
Via MarketMinute
Topics Intellectual Property
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
February 25, 2026
Via MarketMinute
Topics Intellectual Property
News headline image
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
February 25, 2026
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy ↗
February 25, 2026
Via Benzinga

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 145.21
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 03/16/26 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 182.07B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 182B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap